Literature DB >> 8464702

Downregulation of HLA class I expression by c-myc in human melanoma is independent of enhancer A.

L T Peltenburg1, R Dee, P I Schrier.   

Abstract

High constitutive expression of the c-myc oncogene in human melanoma leads to downregulation of expression of HLA Class I genes. The genes at the HLA-B locus are preferentially affected. To investigate the mechanism of downregulation, the activity of the main HLA Class I enhancer, enhancer A-region I, was compared in a panel of c-myc transfectants with increasing myc expression. Gel retardation experiments demonstrated in all tested cell lines binding of the transcription factors KBF1 and NF-kappa B to the enhancer. However, no correlation between the levels of HLA Class I expression and binding to the enhancer could be established. Strikingly, the cell line with the highest c-myc expression showed more binding of KBF1 and NF-kappa B than the parental cell line. By using CAT reporter plasmids in transient transfection assays we investigated the in vivo function of enhancer A-region I in the c-myc transfectant panel. Again, c-myc expression had no effect at all on the activity of enhancer A. This study shows that HLA Class I expression is regulated by the c-myc oncogene at the level of transcription, but that the main HLA Class I enhancer is not involved in this process.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8464702      PMCID: PMC309279          DOI: 10.1093/nar/21.5.1179

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  51 in total

1.  N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma.

Authors:  R Bernards; S K Dessain; R A Weinberg
Journal:  Cell       Date:  1986-12-05       Impact factor: 41.582

2.  Isolation, expression, and the primary structure of HLA-Cw1 and HLA-Cw2 genes: evolutionary aspects.

Authors:  D Güssow; R S Rein; I Meijer; W de Hoog; G H Seemann; F M Hochstenbach; H L Ploegh
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

3.  Molecular cloning of an enhancer binding protein: isolation by screening of an expression library with a recognition site DNA.

Authors:  H Singh; J H LeBowitz; A S Baldwin; P A Sharp
Journal:  Cell       Date:  1988-02-12       Impact factor: 41.582

4.  The nucleotide sequence and comparative analysis of the H-2Dp class I H-2 gene.

Authors:  B S Schepart; H Takahashi; K M Cozad; R Murray; K Ozato; E Appella; J A Frelinger
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

5.  Two transcription factors, NF-kappa B and H2TF1, interact with a single regulatory sequence in the class I major histocompatibility complex promoter.

Authors:  A S Baldwin; P A Sharp
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

6.  DNA sequence analysis of the C3H H-2Kk and H-2Dk loci. Evolutionary relationships to H-2 genes from four other mouse strains.

Authors:  S Watts; J M Vogel; W D Harriman; T Itoh; H J Stauss; R S Goodenow
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

7.  Binding of a nuclear factor to a regulatory sequence in the promoter of the mouse H-2Kb class I major histocompatibility gene.

Authors:  A S Baldwin; P A Sharp
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

8.  Organization, sequence and expression of the HLA-B27 gene: a molecular approach to analyze HLA and disease associations.

Authors:  E H Weiss; W Kuon; C Dörner; M Lang; G Riethmüller
Journal:  Immunobiology       Date:  1985-12       Impact factor: 3.144

9.  Negative regulation of the major histocompatibility class I gene in undifferentiated embryonal carcinoma cells.

Authors:  J Miyazaki; E Appella; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

10.  Purification of KBF1, a common factor binding to both H-2 and beta 2-microglobulin enhancers.

Authors:  O Yano; J Kanellopoulos; M Kieran; O Le Bail; A Israël; P Kourilsky
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  5 in total

Review 1.  Cancer Immunotherapy: Whence and Whither.

Authors:  Peter J Stambrook; John Maher; Farzin Farzaneh
Journal:  Mol Cancer Res       Date:  2017-03-29       Impact factor: 5.852

2.  Transcriptional suppression of HLA-B expression by c-Myc is mediated through the core promoter elements.

Authors:  L T Peltenburg; P I Schrier
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

3.  Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma.

Authors:  Patrick C Lee; Susan Klaeger; Phuong M Le; Keegan Korthauer; Jingwei Cheng; Varsha Ananthapadmanabhan; Thomas C Frost; Jonathan D Stevens; Alan Yl Wong; J Bryan Iorgulescu; Anna Y Tarren; Vipheaviny A Chea; Isabel P Carulli; Camilla K Lemvigh; Christina B Pedersen; Ashley K Gartin; Siranush Sarkizova; Kyle T Wright; Letitia W Li; Jason Nomburg; Shuqiang Li; Teddy Huang; Xiaoxi Liu; Lucas Pomerance; Laura M Doherty; Annie M Apffel; Luke J Wallace; Suzanna Rachimi; Kristen D Felt; Jacquelyn O Wolff; Elizabeth Witten; Wandi Zhang; Donna Neuberg; William J Lane; Guanglan Zhang; Lars R Olsen; Manisha Thakuria; Scott J Rodig; Karl R Clauser; Gabriel J Starrett; John G Doench; Sara J Buhrlage; Steven A Carr; James A DeCaprio; Catherine J Wu; Derin B Keskin
Journal:  J Clin Invest       Date:  2022-07-01       Impact factor: 19.456

4.  Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.

Authors:  K G Paulson; V Voillet; M S McAfee; D S Hunter; F D Wagener; M Perdicchio; W J Valente; S J Koelle; C D Church; N Vandeven; H Thomas; A G Colunga; J G Iyer; C Yee; R Kulikauskas; D M Koelle; R H Pierce; J H Bielas; P D Greenberg; S Bhatia; R Gottardo; P Nghiem; A G Chapuis
Journal:  Nat Commun       Date:  2018-09-24       Impact factor: 14.919

Review 5.  Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy.

Authors:  A Vera de Jonge; Tuna Mutis; Margaretha G M Roemer; Blanca Scheijen; Martine E D Chamuleau
Journal:  Cancers (Basel)       Date:  2020-10-20       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.